loading page

Cystic fibrosis year in review 2021
  • Adrienne Savant
Adrienne Savant
Tulane University School of Medicine

Corresponding Author:[email protected]

Author Profile


People with cystic fibrosis (CF) have an amazing outlook with the treatment availability of highly effective modulators. Unfortunately, not all PwCF are eligible for modulators leading to continued pulmonary exacerbations and advanced lung disease. Additionally, optimizing diagnosis and evaluation for CF in the newborn period continues to be an area of focus for research. This review article will work to cover articles published in 2021 with high clinical relevance related to the above topics, however due to the extensive body of research published, this review will not be comprehensive.
09 Mar 2022Submitted to Pediatric Pulmonology
10 Mar 2022Submission Checks Completed
10 Mar 2022Assigned to Editor
13 Mar 2022Reviewer(s) Assigned
08 Apr 2022Review(s) Completed, Editorial Evaluation Pending
08 Apr 2022Editorial Decision: Revise Minor
13 Apr 20221st Revision Received
16 Apr 2022Submission Checks Completed
16 Apr 2022Assigned to Editor
16 Apr 2022Reviewer(s) Assigned
28 Apr 2022Review(s) Completed, Editorial Evaluation Pending
29 Apr 2022Editorial Decision: Accept
Jul 2022Published in Pediatric Pulmonology volume 57 issue 7 on pages 1590-1599. 10.1002/ppul.25948